UCB partners with Emmy Award winner Ben Decter and Tony Award nominee Kristin Hanggi in their heartfelt musical about living with epilepsy: It's All Your Fault, Tyler Price!
UCB partners with Emmy winner Ben Decter and Tony nominee Kristin Hanggi for the world premiere musical 'It's All Your Fault, Tyler Price!' The musical, focusing on epilepsy awareness, will run from November 7 to December 15, 2024, at The Hudson Theatre in Los Angeles.
The story follows Jackson, a middle school boy who stages a musical to avoid expulsion after punching a classmate who mocked his sister with epilepsy. The cast includes CJ Eldred, Jenna Pastuszek, and Faith Graham. Tickets go on sale August 1, 2024.
UCB, a global biopharmaceutical company, supports this production as part of its commitment to epilepsy awareness and patient care. The musical aims to shed light on Lennox-Gastaut Syndrome (LGS) and other epilepsy-related challenges faced by patients and their families.
UCB collabora con il vincitore dell'Emmy Ben Decter e la nominata al Tony Kristin Hanggi per la prima mondiale del musical 'È tutta colpa tua, Tyler Price!' Il musical, incentrato sulla sensibilizzazione all'epilessia, si svolgerà dal 7 novembre al 15 dicembre 2024, presso il Hudson Theatre di Los Angeles.
La storia segue Jackson, un ragazzo delle scuole medie che mette in scena un musical per evitare l'espulsione dopo aver colpito un compagno di classe che prendeva in giro sua sorella affetta da epilessia. Il cast include CJ Eldred, Jenna Pastuszek e Faith Graham. I biglietti saranno in vendita dal 1 agosto 2024.
UCB, un'azienda biopharmaceutica globale, supporta questa produzione come parte del suo impegno per la sensibilizzazione all'epilessia e la cura dei pazienti. Il musical mira a fare luce su una sindrome di Lennox-Gastaut (LGS) e su altre sfide legate all'epilessia affrontate dai pazienti e dalle loro famiglie.
UCB se asocia con el ganador del Emmy Ben Decter y la nominada al Tony Kristin Hanggi para el estreno mundial del musical '¡Es toda tu culpa, Tyler Price!' El musical, que se centra en la concienciación sobre la epilepsia, se presentará del 7 de noviembre al 15 de diciembre de 2024 en el Hudson Theatre en Los Ángeles.
La historia sigue a Jackson, un chico de secundaria que organiza un musical para evitar la expulsión después de golpear a un compañero de clase que se burló de su hermana con epilepsia. El elenco incluye a CJ Eldred, Jenna Pastuszek y Faith Graham. Las entradas estarán a la venta a partir del 1 de agosto de 2024.
UCB, una empresa biofarmacéutica global, apoya esta producción como parte de su compromiso con la concienciación sobre la epilepsia y la atención al paciente. El musical tiene como objetivo arrojar luz sobre el Síndrome de Lennox-Gastaut (LGS) y otros desafíos relacionados con la epilepsia que enfrentan los pacientes y sus familias.
UCB는 에미 상 수상자인 Ben Decter와 토니 상 후보 Kristin Hanggi와 협력하여 세계 초연 뮤지컬 'It's All Your Fault, Tyler Price!'를 선보입니다. 이 뮤지컬은 간질 인식에 초점을 맞추고 있으며, 2024년 11월 7일부터 12월 15일까지 로스앤젤레스의 허드슨 극장에서 공연됩니다.
이 이야기는 간질이 있는 여동생을 조롱한 급우를 때린 후 퇴학을 피하기 위해 뮤지컬을 준비하는 중학생 잭슨의 이야기를 담고 있습니다. 출연진에는 CJ Eldred, Jenna Pastuszek, Faith Graham이 포함됩니다. 티켓은 2024년 8월 1일부터 판매될 예정입니다.
UCB는 글로벌 생명공학 회사로서 이 제작을 간질 인식과 환자 치료에 대한 의무의 일환으로 지원합니다. 이 뮤지컬은 렌녹스-가스토 증후군 (LGS)과 환자와 그 가족이 직면한 다른 간질 관련 문제들을 조명하는 것을 목표로 합니다.
UCB s'associe avec le lauréat d'un Emmy Ben Decter et la nominée aux Tony Kristin Hanggi pour la première mondiale de la comédie musicale 'C'est toute ta faute, Tyler Price!' Cette comédie musicale, axée sur la sensibilisation à l'épilepsie, se déroulera du 7 novembre au 15 décembre 2024 au Hudson Theatre à Los Angeles.
L'histoire suit Jackson, un collégien qui monte un spectacle pour éviter son exclusion après avoir frappé un camarade qui se moquait de sa sœur atteinte d'épilepsie. La distribution comprend CJ Eldred, Jenna Pastuszek et Faith Graham. Les billets seront en vente à partir du 1er août 2024.
UCB, une entreprise biopharmaceutique mondiale, soutient cette production dans le cadre de son engagement envers la sensibilisation à l'épilepsie et aux soins des patients. La comédie musicale vise à mettre en lumière le Syndrome de Lennox-Gastaut (LGS) et d'autres défis liés à l'épilepsie rencontrés par les patients et leurs familles.
UCB arbeitet mit dem Emmy-Gewinner Ben Decter und der Tony-nominierten Kristin Hanggi zusammen für die Uraufführung des Musicals 'Es ist alles deine Schuld, Tyler Price!' Das Musical, das sich auf Awareness für Epilepsie konzentriert, läuft vom 7. November bis 15. Dezember 2024 im Hudson Theatre in Los Angeles.
Die Geschichte folgt Jackson, einem Schüler der Mittelschule, der ein Musical auf die Beine stellt, um einer Ausweisung zu entgehen, nachdem er einen Mitschüler geschlagen hat, der seine Schwester mit Epilepsie verspottet hat. Die Besetzung umfasst CJ Eldred, Jenna Pastuszek und Faith Graham. Die Tickets gehen am 1. August 2024 in den Verkauf.
UCB, ein globales biopharmazeutisches Unternehmen, unterstützt diese Produktion im Rahmen seines Engagements für Epilepsie-Awareness und Patientenversorgung. Das Musical soll auf das Lennox-Gastaut-Syndrom (LGS) und andere epilesiebedingte Herausforderungen der Patienten und deren Familien aufmerksam machen.
- None.
- None.
- Emmy Award winner Ben Decter and Tony Award nominee Kristin Hanggi announce the full cast for the world premiere musical It's All Your Fault, Tyler Price!
- Music and lyrics by Ben Decter, book by Ben Decter and Kristin Hanggi, directed by Kristin Hanggi
- Performances begin November 7, 2024, and run to December 15, 2024, with the opening on Thursday, November 14, at The Hudson Theatre in
Los Angeles - Tickets go on sale August 1, 2024
It's All Your Fault, Tyler Price! follows Jackson, a middle school boy with big feelings who's in big trouble after punching his bullying classmate, Tyler Price, for mocking Jackson's sister, Lucy. Lucy, who attends the same school's special day class, has epilepsy and related learning challenges. To avoid expulsion, Jackson's principal insists he explain himself to the entire school. In response, Jackson stages a scrappy, heartfelt musical using music he "borrows" from his composer dad. Through each family member's bravery, we watch healing begin for all.
"We're excited to bring It's All Your Fault, Tyler Price! to life," said Kristin Hanggi. "We can't wait to share our incredibly talented cast with
Ben Decter added, "With her warmth and dynamic vision, Kristin has brought together a thrilling, undeniable group of actors to our emerging musical. I cannot wait to watch them in action!"
"We are thrilled to help bring this musical to the stage as a powerful platform to raise awareness for the Lennox-Gastaut Syndrome (LGS) community. Through the universal language of music and performance, this cast and crew shines a spotlight on the challenges faced by those living with epilepsy and their families, including the siblings," stated Laurie Bailey, Patient Advocacy Lead at UCB.
The cast of It's All Your Fault, Tyler Price! features:
CJ Eldred (Off-Broadway's Rock of Ages, First National Tour - The Book of Mormon) as Daniel
Jenna Pastuszek (Off-Broadway's Smile, The Bourbon Room's 44: The Obama Musical) as Emma
Faith Graham (Theatre West's The Wizard of Oz) as Lucy
Charlie Stover (Ahmanson Theatre's A Christmas Story, Global Tour of The Sound of Music) as Jackson
Erin Choi (US Tour – Young Elsa in Disney's Frozen) as Coco
Patrick Ortiz (Broadway's West Side Story;
Dahlya Glick (Upright Citizen Brigade's Quick & Funny Musicals, Geffen Playhouse's A Wicked Soul in Cherry Hill) as Ms. Friss
Desi Dennis-Dylan (CBS's Superior Donuts, ABC's Modern Family, Netflix's Santa Clarita Diet) as Mrs. McKackney
Jonah Orona (The Old Globe's Dr. Seuss's How the Grinch Stole Christmas, San Diego Symphony's Noel, Noel) as Tyler Price
Understudies for It's All Your Fault, Tyler Price! include Lee James (ARTCO's Mack & Mabel; International City Theatre's Into the Breeches and Double V), Shelley Regner (Universal Pictures's Pitch Perfect, Hollywood Bowl in Concert's Beauty and the Beast), Anabelle Skye Greene (South Coast Repertory's A Christmas Carol and Into the Woods), and Jude Schwartz (Netflix's Gabby's Dollhouse) 24th Street Theatre's Julien & Pascale.
The full creative team for It's All Your Fault, Tyler Price! will be announced at a later date.
It's All Your Fault, Tyler Price! begins previews November 7, 2024, with opening night set for Thursday, November 14, at 7:30 p.m. The six-week limited engagement will run through December 15, 2024, at The Hudson Theatre, 6539 Santa Monica Blvd,
It's All Your Fault, Tyler Price! is proud to be supported by the following organizations: UCB, Epilepsy Foundation, Epilepsy Foundation of
ABOUT THE CREATORS
Kristin Hanggi is best known for directing the smash-hit Rock of Ages, for which she received a Tony Award nomination for Best Direction of a Musical. Ms. Hanggi also developed and directed the original
Ben Decter is an Emmy Award-winning composer and songwriter who has created a diverse body of music for TV, theater, and film. Scores include Netflix's "Lucifer," ABC's "Bless This Mess," FOX's "Lethal Weapon," and ABC's "Off the Map" (Shonda Rhimes). His writing has appeared in Hippocampus, Months to Years, Kaleidoscope, and HuffPo. Born in
PHOTO EDITORS:
Photos for the production of It's All Your Fault, Tyler Price! can be found here.
ABOUT UCB
UCB, Brussels,
ABOUT EPILEPSY
Epilepsy is a neurological disorder characterized by recurring, unprovoked seizures, with at least one million people in
For further information:
UCB US Communications
Becky Malone
T: +1.919.605.9600
Email becky.malone@ucb.com
It's All Your Fault, Tyler Price!
Patty Onagan Consulting
T: +1.818.600.8092
Email patty@pattyonagan.com
Forward looking statements
This press release may contain forward-looking statements including, without limitation, statements containing the words "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "continue" and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to differ materially from those that may be expressed or implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring and retention of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, will progress to product approval or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products, which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB's efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB's products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB's data and systems.
Given these uncertainties, you should not place undue reliance on any of such forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labelling in any market, or at any particular time, nor can there be any guarantee that such products will be or will continue to be commercially successful in the future.
UCB is providing this information, including forward-looking statements, only as of the date of this press release. UCB expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.
Additionally, information contained in this document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction.
View original content to download multimedia:https://www.prnewswire.com/news-releases/ucb-partners-with-emmy-award-winner-ben-decter-and-tony-award-nominee-kristin-hanggi-in-their-heartfelt-musical-about-living-with-epilepsy-its-all-your-fault-tyler-price-302208026.html
SOURCE UCB
FAQ
When does 'It's All Your Fault, Tyler Price!' musical premiere?
Who are the creators of 'It's All Your Fault, Tyler Price!' musical?
What is the main theme of 'It's All Your Fault, Tyler Price!' musical?
When do tickets for 'It's All Your Fault, Tyler Price!' go on sale?
How is UCB (UCBJY) involved in 'It's All Your Fault, Tyler Price!' musical?
